Shares of Incyte have moved 0.5% today, and are now trading at a price of $59.82. In contrast, the S&P 500 index saw a -0.0% change. Today's trading volume is 244,817 compared to the stock's average volume of 1,647,965.
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. Based in Wilmington, United States the company has 2,324 full time employees and a market cap of $13,404,944,384.
The company is now trading -27.98% away from its average analyst target price of $83.06 per share. The 16 analysts following the stock have set target prices ranging from $65.0 to $114.0, and on average give Incyte a rating of buy.
Over the last 12 months INCY shares have declined by -12.0%, which represents a difference of -28.0% when compared to the S&P 500. The stock's 52 week high is $86.29 per share and its 52 week low is $58.54. Based on Incyte's average net margin growth of 7.0% over the last 6 years, its core business remains strong and the stock price may recover in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-07 | 3,394,635 | 340,660 | 10 | -68.75 |
| 2022-02-08 | 2,986,267 | 948,581 | 32 | 390.91 |
| 2021-02-09 | 2,666,702 | -295,697 | -11 | -152.38 |
| 2020-02-13 | 2,158,759 | 446,906 | 21 | 250.0 |
| 2019-02-14 | 1,881,883 | 109,493 | 6 | 130.0 |
| 2018-02-15 | 1,536,216 | -313,142 | -20 |
